JP7821159B2 - Bcmaと結合する単一可変ドメイン及び抗原結合分子 - Google Patents

Bcmaと結合する単一可変ドメイン及び抗原結合分子

Info

Publication number
JP7821159B2
JP7821159B2 JP2023509554A JP2023509554A JP7821159B2 JP 7821159 B2 JP7821159 B2 JP 7821159B2 JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023509554 A JP2023509554 A JP 2023509554A JP 7821159 B2 JP7821159 B2 JP 7821159B2
Authority
JP
Japan
Prior art keywords
single variable
variable domain
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023509554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537958A (ja
JP2023537958A5 (cg-RX-API-DMAC7.html
Inventor
子 朋 甄
美 娟 謝
秀 貞 杜
毅 敏 馬
兵 張
同 杰 徐
喜 全 張
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2023537958A publication Critical patent/JP2023537958A/ja
Publication of JP2023537958A5 publication Critical patent/JP2023537958A5/ja
Application granted granted Critical
Publication of JP7821159B2 publication Critical patent/JP7821159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023509554A 2020-08-20 2021-08-16 Bcmaと結合する単一可変ドメイン及び抗原結合分子 Active JP7821159B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842370.5 2020-08-20
CN202010842370 2020-08-20
PCT/CN2021/112756 WO2022037527A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (3)

Publication Number Publication Date
JP2023537958A JP2023537958A (ja) 2023-09-06
JP2023537958A5 JP2023537958A5 (cg-RX-API-DMAC7.html) 2024-08-26
JP7821159B2 true JP7821159B2 (ja) 2026-02-26

Family

ID=80323410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509554A Active JP7821159B2 (ja) 2020-08-20 2021-08-16 Bcmaと結合する単一可変ドメイン及び抗原結合分子

Country Status (6)

Country Link
US (1) US12612635B2 (cg-RX-API-DMAC7.html)
EP (1) EP4202047A4 (cg-RX-API-DMAC7.html)
JP (1) JP7821159B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230045066A (cg-RX-API-DMAC7.html)
CN (1) CN115715325A (cg-RX-API-DMAC7.html)
WO (1) WO2022037527A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170721A (ko) * 2021-04-15 2023-12-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcma를 표적으로 하는 다중 특이성 항체
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942709A (zh) 2019-04-22 2019-06-28 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN109942708A (zh) 2019-03-28 2019-06-28 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
BR112016024546A2 (pt) * 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2019066435A2 (ko) 2017-09-29 2019-04-04 재단법인 목암생명과학연구소 Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
CN111542343B (zh) * 2018-08-24 2023-08-18 上海先博生物科技有限公司 抗bcma的单域抗体及其应用
CN111333729B (zh) 2020-03-17 2022-12-06 深圳市南科生物工程有限公司 抗b细胞成熟抗原的纳米抗体及应用
KR20230170721A (ko) 2021-04-15 2023-12-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcma를 표적으로 하는 다중 특이성 항체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942708A (zh) 2019-03-28 2019-06-28 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709A (zh) 2019-04-22 2019-06-28 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用

Also Published As

Publication number Publication date
US20230193292A1 (en) 2023-06-22
JP2023537958A (ja) 2023-09-06
US12612635B2 (en) 2026-04-28
KR20230045066A (ko) 2023-04-04
EP4202047A4 (en) 2024-09-18
CN115715325A (zh) 2023-02-24
WO2022037527A1 (zh) 2022-02-24
EP4202047A1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN115052895B (zh) 抗SIRPα抗体及其用途
JP7820383B2 (ja) グリピカン-3およびt細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
US12612635B2 (en) BCMA-binding single variable structural domain and antigen-binding molecule
CA3089260A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN113412281A (zh) Btn3a结合蛋白及其用途
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN109721656B (zh) 靶向rankl的治疗性抗体
JP2024541882A (ja) c-Metに結合する抗体及びその使用
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
JP7821161B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2021197401A1 (zh) 结合cd47的抗原结合多肽及用途
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP7851924B2 (ja) 抗trop-2抗体、その抗原結合断片又はその変異体、及びそれらの医学的使用
JP7773237B2 (ja) Cd47に対する単一ドメイン抗体及びその用途
JP7773238B2 (ja) Pd-l1に対する単一ドメイン抗体及びその用途
CN110407942B (zh) 针对kn044的单域抗体
JP2026504831A (ja) TGFβ1結合分子、GARP-TGFβ1結合分子及びそれらの医薬的使用
CN121532424A (zh) Btn3a结合蛋白及其医药用途
CN121895452A (zh) 抗激活素2型受体的抗体及其用途
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821159

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150